Advertisement
Screener

Oncotelic Therapeutics, Inc. (OTLC) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1.9 / 5 stars · 15/40 Roast Me

Oncotelic Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

Oncotelic Therapeutics, Inc. (OTLC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 9.10 million shares for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-12.

Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-04-12

  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 0.00 shares, a 100.00% decline year-over-year.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-12-31 was 1.26M shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-12-31 was 0.00 shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-09-30 was 0.00 shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 9.10M shares, a 28.08% decline from fiscal 2021.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 12.65M shares.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 3.03M shares, a 22.10% increase from fiscal 2017.
  • Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2017 was 2.48M shares, a 3.31% decline from fiscal 2016.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month
2022-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-12
9.10M shares
10-K · filed 2024-04-12
2022-09-309.10M shares
10-Q · filed 2023-11-14
2021-12-311.26M shares
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-20
12.65M shares
10-K/A · filed 2023-04-20
2021-09-3011.39M shares
10-Q · filed 2021-11-22
2018-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10
0.00 shares
derived: sum of 2 quarters · filed 2019-04-10
3.03M shares
10-K · filed 2019-04-10
2018-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14
3.03M shares
10-Q · filed 2018-11-14
2018-06-303.03M shares
10-Q · filed 2018-08-14
2017-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10
0.00 shares
derived: sum of 2 quarters · filed 2019-04-10
364.00K shares
derived: sum of 3 quarters · filed 2019-04-10
2.48M shares
10-K · filed 2019-04-10
2017-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14
364.00K shares
derived: sum of 2 quarters · filed 2017-11-14
2.48M shares
10-Q · filed 2017-11-14
2.81M shares
derived: sum of 4 quarters · filed 2018-04-17
2017-06-30364.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
2.48M shares
10-Q · filed 2017-08-02
2.81M shares
derived: sum of 3 quarters · filed 2018-04-17
2017-03-312.12M shares
10-Q · filed 2017-05-08
2.45M shares
derived: sum of 2 quarters · filed 2018-04-17
2016-12-31331.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-17
2.57M shares
10-K · filed 2018-04-17
2016-09-302.24M shares
10-Q · filed 2016-11-14
2015-12-311.77M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30
1.77M shares
derived: sum of 2 quarters · filed 2017-03-30
1.82M shares
derived: sum of 3 quarters · filed 2017-03-30
1.84M shares
10-K · filed 2017-03-30
2015-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12
50.00K shares
derived: sum of 2 quarters · filed 2015-11-12
75.00K shares
10-Q · filed 2015-11-12
105.00K shares
derived: sum of 4 quarters · filed 2015-11-12
2015-06-3050.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06
75.00K shares
10-Q · filed 2015-08-06
105.00K shares
derived: sum of 3 quarters · filed 2015-08-06
158.00K shares
derived: sum of 4 quarters · filed 2015-08-06
2015-03-3125.00K shares
10-Q · filed 2015-05-07
55.00K shares
derived: sum of 2 quarters · filed 2015-05-07
108.00K shares
derived: sum of 3 quarters · filed 2015-05-07
490.00K shares
derived: sum of 4 quarters · filed 2015-05-07
2014-12-3130.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30
83.00K shares
derived: sum of 2 quarters · filed 2015-03-30
465.00K shares
derived: sum of 3 quarters · filed 2015-03-30
521.00K shares
10-K · filed 2015-03-30
2014-09-3053.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13
435.00K shares
derived: sum of 2 quarters · filed 2014-11-13
491.00K shares
10-Q · filed 2014-11-13
491.00K shares
derived: sum of 4 quarters · filed 2015-03-30
2014-06-30382.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08
438.00K shares
10-Q · filed 2014-08-08
438.00K shares
derived: sum of 3 quarters · filed 2015-03-30
468.00K shares
derived: sum of 4 quarters · filed 2015-03-30
2014-03-3156.00K shares
10-Q · filed 2014-05-08
56.00K shares
derived: sum of 2 quarters · filed 2015-03-30
86.00K shares
derived: sum of 3 quarters · filed 2015-03-30
87.00K shares
derived: sum of 4 quarters · filed 2015-03-30
2013-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30
30.00K shares
derived: sum of 2 quarters · filed 2015-03-30
31.00K shares
derived: sum of 3 quarters · filed 2015-03-30
107.00K shares
10-K · filed 2015-03-30
2013-09-3030.00K shares
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-13
31.00K shares
derived: sum of 2 quarters · filed 2013-11-13
107.00K shares
10-Q · filed 2013-11-13
-1.26M shares
derived: sum of 4 quarters · filed 2015-03-30
2013-06-301.00K shares
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2013-10-18
77.00K shares
10-Q/A · filed 2013-10-18
-1.29M shares
derived: sum of 3 quarters · filed 2015-03-30
-573.00K shares
derived: sum of 4 quarters · filed 2015-03-30
2013-03-3176.00K shares
10-Q · filed 2013-05-09
-1.29M shares
derived: sum of 2 quarters · filed 2015-03-30
-574.00K shares
derived: sum of 3 quarters · filed 2015-03-30
2012-12-31-1.36M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30
-650.00K shares
derived: sum of 2 quarters · filed 2015-03-30
124.00K shares
10-K · filed 2015-03-30
2012-09-30714.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09
1.49M shares
10-Q · filed 2012-11-09
2012-06-30774.00K shares
10-Q · filed 2012-08-13
2011-12-3170.00K shares
10-K · filed 2014-03-20
2010-12-3121.00K shares
10-K · filed 2013-03-15